CCO Neuroscience Podcast

Link to CME: Claim Credit - https://bit.ly/3OByCaEIn this episode, Drs. Halford and Hahn discuss the current treatment landscape of developmental and epileptic encephalopathies (DEEs), such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency. The full episode covers:How to diagnose these epilepsies and the FDA-approved treatment options in the first-line and second-line settingsThe role of antiseizure medications in DEE treatment managementThe nonpharmacological treatment options available to patients with DEEsThe emerging role of brain cholesterol in neurologic diseases like DEEs and Alzheimer’s diseaseResults from the ELEKTRA clinical trial, including cholesterol synthase inhibitors’ impact on seizure frequencyThe future of soticlestat as a treatment option for pediatric patients with DEEsPresenters:Jonathan J. Halford, MDProfessorDirector, Translational Research UnitDepartment of NeurologyMedical University of South CarolinaCharleston, SCCecil Hahn, MD, MPH, FRCPCProfessorPediatric EpileptologistUniversity of TorontoToronto, Ontario, CanadaContent based on an online CME program supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.Link to full program: https://bit.ly/45UUpQy

Link to CME: Claim Credit - https://bit.ly/3wbVkA1In this episode, Drs. Halford and White discuss the emerging role of brain cholesterol in the development and potential treatment of neurological diseases like epilepsy or Alzheimer and Huntington diseases. The full episode covers:Overview of brain cholesterol and its function in the bodyPathogenesis potential for certain diseases via brain cholesterolEmerging research on a cholesterol synthase inhibitor as a novel therapyThe future of soticlestat as a potential treatment option for pediatric epilepsies—Lennox-Gastaut syndrome and Dravet syndrome—and other neurological diseasesPresenters:Jonathan J. Halford, MDProfessorDirector, Translational Research UnitDepartment of NeurologyMedical University of South CarolinaCharleston, SCH. Steve White, PhDProfessor, Department of PharmacyCo-Director, Center for Epilepsy Drug DiscoverySchool of PharmacyUniversity of WashingtonSeattle, Washington

In this episode, Drs. Sabbagh and Isaacson discuss how to best approach Alzheimer’s disease (AD) and mild cognitive impairment (MCI) in clinical practice, including accurately diagnosing patients and optimizing treatment in terms of patient preferences and reimbursement options. The full episode covers:Defining AD and MCI and their clinical presentationHow to diagnose AD vs MCIReimbursement landscape for current diagnosing and monitoring toolsPrecision medicine’s evolving role in diagnosing and treating patients with AD and/or MCI Presenters:Marwan Sabbagh, MDProfessor of NeurologyAlzheimer’s and Memory Disorders DivisionDepartment of NeurologyBarrow Neurological InstitutePhoenix, ArizonaRichard Isaacson MDDirector of the Institute for Neurodegenerative DiseasesFlorida 

The treatment landscape of major depression is increasingly shifting from monoaminergic agents to agents that modulate glutamate and GABA. Healthcare professionals need to stay up to date and educated on these changes in order to discuss the most current treatment options with their patients. In this podcast episode, we interview Dr Anita Clayton, a clinician researcher who has been involved in some of the clinical trials for these novel glutamatergic and GABAergic medications, and ask her key questions about mechanism of action and clinical application. Listeners will come away from this podcast episode more informed and more excited for the future of major depression care. Presenters:Anita Clayton, MDDavid C. Wilson Professor and ChairDepartment of Psychiatry and Neurobehavioral SciencesProfessor of Clinical Obstetrics and GynecologyUniversity of Virginia School of MedicineCharlottesville, VirginiaThis podcast episode is supported by an educational grant from Sage Therapeutics, Inc. and Biogen.Link to full program:https://bit.ly/3YdPMPa

Rett syndrome is a rare but severe neurodevelopmental disorder, and current treatment approaches primarily focus on symptom management and supportive care. However, recent clinical developments are providing hope for a changing treatment landscape. In this podcast episode, experts in Rett syndrome David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, discuss trofinetide and blarcamesine, 2 agents in late-stage clinical trials as treatment options for Rett syndrome. Throughout their conversation, Drs Lieberman and Neul review the pivotal LAVENDER, DAFFODIL, AVATAR, and EXCELLENCE trials, including information on the safety and efficacy profiles of trofinetide and blarcamesine. The experts end their discussion with a conversation about the potential roles of ketamine and gene therapy in the management of Rett syndrome.      Presenters:David N. Lieberman, MD, PhDInstructorDepartment of NeurologyHarvard Medical SchoolAttending PhysicianChild NeurologyBoston Children’s HospitalBoston, MassachusettsJeffrey Neul, MD, PhDDirectorPediatricsVanderbilt University Medical CenterNashville, TennesseeThis activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.To claim CME/CE credit for this podcast, complete the posttest here: bit.ly/3JR4qq5.For additional activities in this program, visit bit.ly/3JR4qq5 

Rett syndrome affects many organ systems, and each patient has individual symptoms and experiences—there is no “one-size-fits-all” treatment approach. In this podcast episode, Rett syndrome experts David N. Lieberman, MD, PhD, and Shannon Standridge, DO, MPH, discuss some of the more common manifestations of Rett syndrome and current management strategies. While covering manifestations such as epilepsy, behavioral issues, and gastrointestinal distress, they highlight the value of a team approach to help the patient thrive. Throughout their conversation, Drs Lieberman and Standridge weave in real-world examples of interactions they have had with families of patients with Rett syndrome and offer insights on communication strategies for different aspects of management.Presenters:David N. Lieberman MD, PhDInstructorDepartment of NeurologyHarvard Medical SchoolAttending PhysicianChild NeurologyBoston Children’s HospitalBoston, MassachusettsShannon Standridge, DO, MPHProfessorDivision of NeurologyVinaya Rett Syndrome and Related Spectrum Disorders ClinicCincinnati Children’s Hospital Medical CenterCincinnati, OhioThis activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.To claim CME/CE credit for this podcast, complete the posttest here: http://bit.ly/41CeaePFor additional activities in this program, visit http://bit.ly/3lXuzda

In this podcast episode, Leslie Citrome, MD, MPH, and Adam Lowy, MD, share a wealth of knowledge about long-acting injectable (LAI) antipsychotics. Their conversation begins with an overview of the pharmacokinetic profiles of LAI antipsychotics and how they differ from their oral counterparts, as well as injection intervals available with current formulations. The experts also discuss the clinical utility of LAI antipsychotics in psychiatry practice, highlighting their role in assuring medication adherence and their application in both first- and later-episode psychosis. Finally, Drs Citrome and Lowy hit on practical aspects of incorporating LAI antipsychotics into patient care: communicating with patients to dispel myths and stigma surrounding injectable medications, identifying injection resources in your medical community, and strategies to navigate insurance barriers.Throughout the podcast, Drs Citrome and Lowy reference several links to outside sources that can provide valuable education on LAI antipsychotics. Those links are listed below for your convenience.Administering LAI Into Dorsal Gluteal Site: https://bit.ly/3XjSm5aAdministering LAI Into Deltoid Site: https://bit.ly/3Xlyq1LAdministering LAI Into Abdominal Site: https://bit.ly/3wgGJ2ZPresenters:Leslie Citrome, MD, MPHClinical ProfessorDepartment of Psychiatry and Behavioral SciencesNew York Medical CollegeValhalla, New YorkAdam Lowy, MDStaff PsychiatristEllenhornLos Angeles, CaliforniaThis activity is supported by educational funding provided byOtsuka America Pharmaceutical, Inc. and Lundbeck.For additional activities in this program, visit:https://bit.ly/3iM0HiP

In this podcast episode, experts in Rett syndrome, David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, provide a comprehensive overview of Rett syndrome (RTT), a rare but severe neurodevelopmental disorder. They begin with a discussion on the clinical characteristics and typical disease progression of RTT before diving into the various genetic markers and how they may, or may not, be used in the diagnosis and prognosis. Finally, the experts ponder the future of RTT diagnoses, touching upon how we might identify RTT and intervene earlier, potential utilization of biomarkers, and the role of measurement-based care.Presenters:David N. Lieberman MD, PhDInstructorDepartment of NeurologyHarvard Medical SchoolAttending PhysicianChild NeurologyBoston Children's HospitalBoston, MassachusettsJeffrey Neul MD, PhDDirectorPediatricsVanderbilt University Medical CenterNashville, TennesseeThis activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.To claim CME/CE credit for this podcast, complete the posttest here:https://bit.ly/3WjtMjAFor additional activities in this program, visit:https://bit.ly/3kfAn0U

In this podcast episode, epileptologists Aatif Husain, MD, and John Stern, MD, have a conversation about rescue therapies and how they fit into the spectrum of epilepsy management. Their discussion begins with sharing what they consider the utility of rescue therapies to be in the overall spectrum of epilepsy. As the conversation goes on, they address the role of rescue therapies in more specific patient populations, such as the newly diagnosed patient, a patient experiencing seizure clusters, and patients who may be experiencing either very few or relatively many breakthrough seizure events. In all scenarios, the experts relate the use of rescue therapies as “insurance”—hoping that the agents don’t have to be used, but having them available as coverage in the worst-case scenario. The podcast goes on to discuss rescue therapies in terms of available routes and mechanisms of action and practical strategies for talking to patients about these agents. Rounding out the episode, Drs Husain and Stern express their hopes for future developments in epilepsy management.Presenters:Aatif Husain, MDProfessorDivision of Epilepsy, Sleep and Clinical NeurophysiologyDepartment of NeurologyDuke University Medical CenterDurham, North CarolinaJohn Stern, MDProfessorNeurologyGeffen School of Medicine, UCLADirectorEpilepsy Clinical ProgramUCLA Department of NeurologyLos Angeles, CaliforniaThis content is based on a CE/CME program supported by an independent educational grant from Neurelis, Inc.For additional activities in this program, visit https://bit.ly/3GiLlu4.

In this podcast episode, Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, have a conversation about Parkinson’s disease psychosis (PDP). Their discussion provides information on the disease itself—covering symptoms, risk factors, and mechanism—before moving into clinical strategies for diagnosis and disease and comorbidity management. The experts emphasize the importance of ruling out an underlying cause of psychosis before making a diagnosis of PDP, calling out common culprits such as urinary and respiratory tract infections. Following diagnosis, they comment on the value of implementing nonpharmacologic measures in tandem with pharmacologic interventions for PDP. Within the discussion of pharmacologic interventions, Drs Sabbagh and San Luciano give a well-rounded explanation of patient and medication factors they consider when choosing a treatment for their patients with PDP, including patient outcomes they have experienced in clinical practice. Rounding out the podcast, the experts touch on their approach to managing the very common comorbidity of sleep disturbances in patients with PDP.Presenters:Marwan Sabbagh, MD, FAANProfessor of NeurologyAlzheimer's and Memory Disorders DivisionDepartment of NeurologyBarrow Neurological InstitutePhoenix, ArizonaMarta San Luciano, MD, MS, FAANAssociate Professor of NeurologyUniversity of California, San FranciscoAttending NeurologistNeurology/Movement Disorders and Neuromodulation CenterUniversity of California, San Francisco Medical CenterSan Francisco, CaliforniaThis content is based on a CE/CME program supported by an independent educational grant from Acadia Pharmaceuticals, Inc.For additional activities in this program, visithttp://bit.ly/3tPMqnr

In this episode, Christoph U. Correll, MD, and John M. Kane, MD, discuss the various etiologies of tardive dyskinesia (TD). Although most healthcare professionals are aware of the risk for TD that comes with first- and second-generation antipsychotic use, there is less awareness around other modifiable and unmodifiable factors that increase risk for TD development. Some modifiable risks include metoclopramide use, anticholinergic use, and substance use disorder; unmodifiable risks include older age and female sex. The doctors agree that, regardless of the level of risk, careful documentation and evaluation should be conducted with patients to detect TD early—should it develop. Their conversation rounds out with considerations for treatment approaches and clinical pearls garnered from years in practice.Presenters:Christoph U. Correll, MDProfessor of Psychiatry and Molecular MedicineThe Donald and Barbara Zucker School of Medicine at Hofstra/NorthwellNew York, New YorkProfessor of Child and Adolescent PsychiatryCharité – Universitätsmedizin BerlinBerlin, GermanyJohn M. Kane, MDVice President for Behavioral Health ServicesNorthwell HealthChairman of PsychiatryZucker Hillside HospitalQueens, New YorkChairman of PsychiatryProfessor of Psychiatry and Molecular MedicineZucker School of Medicine at Hofstra/NorthwellHempstead, New YorkFor more programs in this series, visit:https://bit.ly/3AhRXau

In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the ongoing bipolar disorder research and developments expected to have an impact in the coming year. They elaborate on the various  neurotransmitters being investigated and how this research might change the future of patient care. From investigating new mechanisms of action to increased uptake of more novel therapeutics such as esketamine and neuromodulation, there is a lot to look forward to. As they note in the podcast: It’s an exciting time to be in the field of brain science!Presenters:Greg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriVladimir Maletic MDClinical ProfessorDepartment of PsychiatryUSC School of MedicineGreenville, South CarolinaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.For more programs in this series, visit:https://bit.ly/3ft1rYI

Get answers to the questions that you and your colleagues have asked! In this episode, Jonathan M. Meyer, MD; Leslie Citrome, MD, MPH; and Stuart Isaacson, MD, provide answers to audience questions that were submitted at recent CCO Psychiatry meetings. Their thoughtful responses cover your questions on screening, communicating with patients, medication management, and more. Moderators Rajesh Pahwa, MD; Charles DeBattista, DMH, MD; and Greg W. Mattingly, MD, provide complementary commentary throughout the question and answer session, adding interprofessional perspective to the activity.Presenters:Leslie Citrome, MD, MPHClinical ProfessorDepartment of Psychiatry and Behavioral SciencesNew York Medical CollegeValhalla, New YorkCharles DeBattista, DMH, MDChiefDepression Research ClinicDirectorMedical Student Education in PsychiatryProfessor of Psychiatry and Behavioral SciencesStanford University School of MedicineStanford, CaliforniaStuart Isaacson, MDDirectorParkinson's Disease and Movement Disorders Center of Boca RatonBoca Raton, FloridaClinical Associate Professor of NeurologyFIU Herbert Wertheim College of MedicineMiami, FloridaGreg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriJonathan M. Meyer MDVoluntary Clinical Professor, Department of PsychiatryUniversity of California, San DiegoPsychopharmacology ConsultantBalboa Naval Medical Center First Episode Psychosis ProgramState of Nevada Project ECHO First Episode Psychosis ProgramRajesh Pahwa, MDChief, Parkinson and Movement Disorder DivisionDirector, Parkinson Foundation Center of ExcellenceUniversity of Kansas Medical CenterKansas City, KansasFor more programs in this series, visit: https://bit.ly/3Bg0oTv

In this episode, Joseph F. Goldberg, MD, and Roger McIntyre, MD, FRCPC, shed light on the symptom improvement timeline in bipolar depression. This is a topic made more complex when factoring in individual patient characteristics and comorbidities, but the 2 experts have astute insights on how to tailor a management plan based on such factors. They cover symptom management and improvement from a variety of angles, including evaluating improvement in functionality and mood, guidance on follow-up and dose adjustment schedules, the utility of measurement-based care, and—of most importance—how to best communicate with and support a patient while they work towards remission and recovery.Presenters:Joseph F. Goldberg, MDClinical Professor of PsychiatryDepartment of PsychiatryIcahn School of Medicine at Mount SinaiNew York, New YorkRoger McIntyre, MD, FRCPCProfessor of Psychiatry and PharmacologyDepartment of Psychiatry/PharmacologyUniversity of TorontoHead, Mood Disorders Psychopharmacology UnitDepartment of PsychiatryToronto, CanadaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.For more programs in this series, visit:https://bit.ly/3ft1rYI

In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia from identification to follow-up and ongoing management. They provide valuable insights on pharmacologic options to both consider and avoid to optimize outcomes in patients with tardive dyskinesia, including a focus on clinical strategies for use of VMAT2 inhibitors.Presenters:Robert O. Cotes, MDAssociate ProfessorDepartment of Psychiatry and Behavioral SciencesEmory University School of MedicineAtlanta, GeorgiaJonathan M. Meyer, MDVoluntary Clinical Professor, Department of PsychiatryUniversity of California, San DiegoPsychopharmacology ConsultantBalboa Naval Medical Center First Episode Psychosis ProgramState of Nevada Project ECHO First Episode Psychosis Program

In this podcast episode, Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, provide a wealth of information on VMAT2 inhibitors and their use for tardive dyskinesia (TD) management. Their discussion includes information on VMAT2 inhibitor emergence in clinical practice, mechanism of action, adverse event profiles, insurance coverage, and strategies for initiation and titration. In addition to VMAT2 inhibitors, the experts touch on off-label options for TD management and their place in the TD management paradigm.Presenters:Diana O. Perkins, MD, MPHProfessor, PsychiatryUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaRajiv Tandon, MDEmeritus Professor of PsychiatryDepartment of PsychiatryWestern Michigan University Homer Stryker MD College of MedicineKalamazoo, MichiganThis content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences.For more programs in this series, visit:https://bit.ly/3yOL8f7

In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, share their thoughts on treatment strategies across the bipolar depression spectrum. They begin by talking about their stance on treating bipolar with comorbidities with a holistic vs stepwise approach and discuss what strategies they would consider for a patient not yet diagnosed with but who is at risk of developing bipolar depression. In addition, they discuss the concept of phase-specific treatment, considerations for medication-related adverse events, and the utility of adjunctive measures for managing bipolar depression. Presenters:Greg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriVladimir Maletic MDClinical ProfessorDepartment of PsychiatryUSC School of MedicineGreenville, South CarolinaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.For more programs in this series, visit: https://bit.ly/3TClDqb

In this podcast episode on tardive dyskinesia (TD), Joseph P. McEvoy, MD, interviews Leslie, a patient who was diagnosed with TD 10 years ago. She describes her journey to an accurate diagnosis, the impact that TD has on her daily life, and her advice for patients and providers affected by TD.Presenters:Joseph P. McEvoy MDProfessorPsychiatry and Health BehaviorPsychiatristAugusta UniversityAugusta, GeorgiaLeslieThis content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.For more programs in this series, visit:https://bit.ly/3dUCVi6

In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the complexities of accurately diagnosing bipolar depression. Bipolar depression can be difficult to differentiate from other psychiatric conditions, such as unipolar depression, depression with mixed features, ADHD, PTSD, and anxiety. This differential is made more challenging in that patients with bipolar depression often have psychiatric comorbidities with overlapping symptomology. Listen as the 2 psychiatrists share their insights on how to act as detectives and weed through clues from current symptoms, past symptoms, and family history to reach an accurate diagnosis. Presenters:Greg W. Mattingly, MDAssociate Clinical Professor PsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriVladimir Maletic MDClinical ProfessorDepartment of PsychiatryUSC School of MedicineGreenville, South CarolinaThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.For more programs in this series, visit: https://bit.ly/3TClDqb

Get answers to the questions that you and your colleagues have asked! In this episode, Charles DeBattista, MD, provides answers to audience questions that were submitted at 2 recent Psychiatry Update meetings. His thoughtful responses cover your questions on differential diagnosis, initiating pharmacotherapy, medication management, and more. Moderators Amber Hoberg, PMHNP, and Greg W. Mattingly, MD, provide complementary commentary throughout the Q&A session, adding interprofessional perspective to the activity.Presenters:Charles DeBattista, DMH, MDChiefDepression Research ClinicDirectorMedical Student Education in PsychiatryProfessor of Psychiatry and Behavioral SciencesStanford University School of MedicineStanford, CaliforniaAmber Hoberg, PMHNPNurse PractitionerMorningStar Family MedicineFloresville, TexasGreg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriThis content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.For more programs in this series, visit:https://bit.ly/3cX8ebyRegister for our Psychiatry Update 2022 series. This program is free and will offer up to 5 CME/CE credits. For physicians (MD, DO), psychiatry specialist NPs and PAs, pharmacists, social workers, and psychologists, register at:https://bit.ly/3Q1WLWRFor NPs and PAs in primary care/other specialties, register at:https://bit.ly/3Jf54Ma